Puma Biotechnology (PBYI) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

52NeutralDD: Aug 22, 2026Analyst: 48

paidPrice at analysis date

USD 8.82 (22/08/2026)

domainMkt cap

$460M

pie_chartShares

51.62M

candlestick_chart52W

2026-08

trending_downShort interest

MEDIUMNASDAQHealth Care179 employeesFounded 2010

Verdict: Caution — Momentum ≠ Value

Single-product commercial biotech (Nerlynx / neratinib) with a strong Q2 2026 beat-and-raise, debt-free balance sheet and $94M cash, but expected earnings compression (FY26 net income guidance $17-20M vs $31M in FY25, consensus FY27 EPS $0.11 vs $0.50 TTM). Stock is trading near 52W high on momentum while forward P/E of ~30x is inconsistent with a decelerating single-asset franchise. Consensus analyst PT $6.00 (TD Cowen, 8 days ago) implies −32% to current $8.82. Fair value work below concludes the stock is overvalued relative to fundamentals; the MOMENTUM tag was a screening criterion only.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-08-22

Puma Biotechnology (PBYI)

Biotechnology / HER2+ Breast Cancer · NASDAQ · Los Angeles

"Profitable, debt-free, but priced for growth the pipeline does not yet support."

Debt-free Forward P/E 30x Q2 EPS beat Single asset $94M cash

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — P/E on FY26 guided EPS + Net cash + Pipeline option − Patent-cliff haircut

Fair value base case

USD 5.90

Range: USD 4.00-USD 8.50

Price at analysis date: USD 8.82 (22/08/2026)

Base upside/downside: -33%

peer-blended P/E on FY26 guided EPS + explicit net cash + pipeline option ≤10% of base FV + patent-cliff haircut. Implied EV/EBITDA 6.6x within ±20% of peer median (5.5x). Cross-check EV/Sales 0.93x consistent with mature declining commercial biotechs. Base FV $5.93 vs analyst consensus $6.00 → within 1%, corroborating. Sensitivity: −33% downside to current $8.82 driven mainly by the fact that current multiple prices in growth that guidance does not support. ⚠️ Not investment advice.

Component	Assumption	USD/share
Nerlynx US commercial core	FY26E EPS $0.36 × 8.0x P/E (peer-blended, decline-adjusted)	+2.88
OUS royalty stream	FY26E royalty $21.5M × 3.5x (mid-duration, declining)	+1.46
Net cash (debt-free)	$93.9M cash / 51.62M shares (30 Jun 2026)	+1.82
Alisertib pipeline option	12% probability × $150M NPV / 51.62M sh	+0.35
Nerlynx patent-cliff haircut	PV of 2030+ generic entry, −20% on core Nerlynx value	−0.58
FV base case	Sum of rows above: 2.88 + 1.46 + 1.82 + 0.35 − 0.58	≈ $5.93

Bull

$8.00–10.50

Probability: 15%

Alisertib Phase II positive readout (H2 2026), Nerlynx demand accelerates via new indications, partnership monetizes OUS rights, pipeline re-rated. Multiple expands to 12x on stable EPS.

Base

$5.00–7.00

Probability: 55%

Nerlynx plateau at $220-230M revenue, gradual FCF harvest, no pipeline surprise. Multiple compresses to 6-8x forward on declining EPS. Analyst consensus $6.00 anchors the level.

Bear

$3.00–4.50

Probability: 30%

Earlier-than-expected generic Nerlynx entry (2028-29), alisertib fails Phase II, revenue erodes toward $180M, dividend/buyback pressure. Multiple contracts to 4x on FY27 EPS $0.11.

Methodology: peer-blended P/E on FY26 guided EPS + explicit net cash + pipeline option ≤10% of base FV + patent-cliff haircut. Implied EV/EBITDA 6.6x within ±20% of peer median (5.5x). Cross-check EV/Sales 0.93x consistent with mature declining commercial biotechs. Base FV $5.93 vs analyst consensus $6.00 → within 1%, corroborating. Sensitivity: −33% downside to current $8.82 driven mainly by the fact that current multiple prices in growth that guidance does not support. ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: single-product commercial biotech. Valuation uses P/E on FY26 guided EPS plus net cash, cross-checked with EV/EBITDA vs mature commercial biotech peers (HRMY, COLL, CORT). Pipeline (alisertib) valued as an option (probability × NPV) with cap ≤15% of base case. Nerlynx US composition patent expires around 2030 — patent-cliff haircut modeled as a separate FV line.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~7%

Moderate short interest on 40.16M float. Days-to-cover ~2. Recent momentum has forced modest covering; not a squeeze setup.

🟢 Share dilution (1Y)

~+1%

Shares outstanding 51.62M (vs ~51M prior year). Marginal dilution from equity comp inducement grants (Nasdaq Rule 5635(c)(4) reported July 2026).

🔴 Buyback

No active repurchase program. Cash prioritized on debt payoff (completed Q2 2026) and pipeline. Missed opportunity given $94M cash and stock at forward P/E 30x.

Short Interest — context

PBYI — ~7%

~7%

Interpretation: moderate short interest reflects the market's split view — bulls playing the Q2 beat/raise + debt-free story, bears anticipating FY27 EPS collapse and patent cliff. No squeeze catalyst.

$Financial analysis — FY 2023-2026E

Revenue TTM

$231M

−2.9% YoY

Net Income TTM

$26.7M

−44.9% YoY

Cash & Equivalents

$93.9M

Debt-free (Q2 2026)

FY26 Net Income guide

$17-20M

−40% vs FY25

Item	FY23	FY24	FY25	FY26E (guide)	FY27E (consensus)
Revenue ($M)	218	230	228	228 (mid)	~205
Net income ($M)	28	30	31	18.5 (mid)	~6
EPS ($)	0.60	0.62	0.62	0.36	0.11
Cash EoP ($M)	65	85	97.5	~100	~110
Debt ($M)	45	23	11	0	0

Guidance from Q2 2026 earnings call (Aug 6). Consensus FY27 reflects 2 analysts (thin coverage). Revenue flat, earnings compressing due to fully-loaded R&D on alisertib and OpEx normalization.

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	52.4	55.1	75.5	44.8	56.5
Gross margin %	~78%	~78%	~80%	~76%	~78%
Net income ($M)	7.0	8.4	13.6	−2.1	9.8
End-of-period cash ($M)	81.2	85.4	97.5	96.0	93.9

Financial position and sustainability

Cash coverage (yrs of OpEx)

>5y

FCF margin (TTM)

~19%

Nerlynx revenue concentration

100%

account_tree

Business model — Single-product commercial oncology biotech

Nerlynx (neratinib) — HER2+ breast cancer, extended adjuvant & metastatic

Puma is a single-asset commercial biotech: 100% of revenue derives from Nerlynx, an oral tyrosine kinase inhibitor approved in the US and via royalty partners in EU, Asia and LatAm. Two indications: (1) extended adjuvant for early-stage HER2+ breast cancer post-trastuzumab, (2) advanced/metastatic HER2+ combined with capecitabine. US net product revenue tracks ~$180-190M; OUS royalty stream ~$20-23M. Pipeline: alisertib (aurora kinase A inhibitor) in Phase II for HR+ breast cancer and small cell lung cancer, with interim readouts expected 2026-27.

gavel

Legal, regulatory and risk analysis

Single-asset concentration

Critical

100% of revenue from Nerlynx. Any FDA label change, safety signal or competitive event is existential. No revenue diversification through 2028.

Patent cliff (2030)

High

Nerlynx US composition-of-matter patent expires around 2030. Method-of-use claims may extend life but generic entry is near-line-of-sight. Modeled as −20% haircut on Nerlynx PV in base FV.

Earnings compression FY26-27

High

Management guides FY26 net income $17-20M vs $31M in FY25 (−40%). Consensus FY27 EPS $0.11 vs TTM $0.50 (−78%). Forward P/E 30x is inconsistent with this profile.

Pipeline binary (alisertib)

Moderate

Alisertib Phase II readouts in HR+ BC and SCLC are the only non-Nerlynx catalysts. Positive data could reset the story; failure removes the last lever for multiple expansion.

Diarrhea tolerability / label

Moderate

Nerlynx diarrhea profile has historically capped demand and prescriber willingness. Loperamide prophylaxis has helped but limits pricing power and label expansion.

Debt-free balance sheet

Positive

Final $11.1M Athyrium payment made in Q2 2026. Now debt-free with $94M cash, ~5+ years of OpEx cushion even in a decline scenario.

FCF-generative + profitable

Positive

Rare small-cap commercial biotech that generates real GAAP earnings and FCF (~$0.83/share cash flow). Not a going-concern story.

Insider selling / governance

Low

No material Form 4 selling in last 12 months disclosed. No active class action or SEC investigation. Standard proxy filing (April 2026). Governance not a red flag.

article

SWOT analysis

Strengths

+Debt-free with $94M cash (~20% of market cap)
+Profitable and FCF-generative, unusual for small-cap biotech
+Q2 2026 beat: EPS $0.19 vs $0.10 consensus (+90%)
+Established commercial infrastructure in US and OUS royalty network

Weaknesses

−100% single-asset concentration on Nerlynx
−Forward P/E 30x with declining EPS is a valuation gap
−No buyback despite $94M cash and low absolute price
−Thin analyst coverage (2 analysts), consensus PT well below spot

Opportunities

→Alisertib Phase II data (HR+ BC + SCLC) could reset the pipeline story
→In-licensing or M&A using $94M net cash to add a second asset
→OUS royalty stream monetization / partnership
→Potential dividend or buyback initiation if pipeline stalls

Threats

!Nerlynx patent expiration ~2030 → generic entry pressure
!Competition in HER2+ setting (T-DM1, T-DXd, tucatinib)
!Soft Q3 2026 guidance already tempered post-earnings reaction
!Momentum unwind if alisertib misses or FY27 guidance disappoints

article

Summary by assessment area

🟢 Balance-sheet risk — Low

$94M cash, zero debt
5+ years of OpEx cushion
Positive net income and FCF

🟡 Business-model risk — Moderate/High

Single-asset concentration (Nerlynx)
Patent cliff in ~2030
Pipeline unproven (alisertib Phase II)

🔴 Valuation risk — High

Forward P/E 30x vs peers 5-9x
Analyst PT $6 vs price $8.82 (−32%)
FY27 EPS consensus $0.11 not priced in

{ "verdict_label": {"it": "Giudizio: Cautela — Momentum non equivale a valore", "en": "Verdict: Caution — Momentum is not value"}, "verdict_text": {"it": "PBYI e' una commercial biotech mono-prodotto (Nerlynx) profittevole e senza debito, ma con guidance FY26 di utili in calo (−40%) e consenso FY27 a EPS $0.11 vs TTM $0.50. Forward P/E 30x incoerente con il profilo di declino. Fair value $5.90 vs prezzo $8.82: overvalued del 33%. Target analisti $6.00.", "en": "PBYI is a single-product commercial biotech (Nerlynx), profitable and debt-free, but with FY26 net-income guidance −40% YoY and FY27 consensus EPS $0.11 vs TTM $0.50. Forward P/E 30x is inconsistent with the decline. Fair value $5.90 vs price $8.82: 33% overvalued. Analyst PT $6.00."}, "bull_points": [ {"it": "Debt-free con $94M di cassa e Q2 2026 EPS $0.19 vs consenso $0.10", "en": "Debt-free with $94M cash and Q2 2026 EPS $0.19 vs $0.10 consensus"}, {"it": "Rara small-cap biotech gia' profittevole e cash-generative", "en": "Rare small-cap biotech already profitable and cash-generative"}, {"it": "Alisertib Phase II readout H2 2026 puo' resettare la pipeline story", "en": "Alisertib Phase II readout in H2 2026 could reset the pipeline story"} ], "bear_points": [ {"it": "100% dei ricavi da Nerlynx; patent cliff ~2030", "en": "100% revenue from Nerlynx; patent cliff ~2030"}, {"it": "Forward P/E 30x incoerente con EPS in calo verso $0.11", "en": "Forward P/E 30x inconsistent with EPS falling toward $0.11"}, {"it": "Nessun buyback nonostante $94M di cassa e stock vicino al top 52W", "en": "No buyback despite $94M cash and stock near 52W high"} ], "risks": [ {"it": "Compressione multipli su prima guidance FY27 (Feb 2027)", "en": "Multiple compression on first FY27 guidance (Feb 2027)"}, {"it": "Fallimento alisertib rimuove l'unica leva di re-rating", "en": "Alisertib failure removes the only re-rating lever"}, {"it": "Ingresso generici anticipato accelera la discussione sul terminal value", "en": "Earlier generic entry accelerates terminal-value discussion"} ] }

Sources & Disclaimer

Sources: Puma Biotechnology Q2 2026 earnings release & call transcript (2026-08-06, Business Wire / stockanalysis.com), MarketBeat PBYI page, StockAnalysis.com PBYI overview, Yahoo Finance PBYI quote, TD Cowen note (price target raised to $6, Hold, 2026-08-14), Zacks Q2 2026 earnings recap, Simply Wall St financial health, Trefis 52-week-high list (2026-08-19). Market data — last verified close 2026-08-21: PBYI ~$8.82, market cap ~$460M, 52W: $3.05-$9.40, shares outstanding 51.62M. Short interest: ~7% of float. FY26 guidance: revenue $224-231M, net income $17-20M. Cash (30 Jun 2026): $93.9M, debt: $0. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.